SCHEMBL874054

SCHEMBL874054

COc1ccc(CC=O)cc1F

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
PPARG P37231 1/20 0.49
PPARD Q03181 1/20 0.49
PPARA Q07869 1/20 0.49
HTT P42858 4/20 0.48
KDM4E B2RXH2 1/20 0.48
MITF O75030 1/20 0.48
LMNA P02545 3/20 0.47
RAB9A P51151 2/20 0.47
MAPK1 P28482 2/20 0.47
CYP17A1 P05093 1/20 0.46
TUBB1 Q9H4B7 1/20 0.46
DBH P09172 1/20 0.46
NPC1 O15118 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ERN1 O75460 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL584542 0.86 KDM4E (0.47) ALDH1A1HTTKDM4EMITFLMNA
SCHEMBL2554927 0.85 ALDH1A1 (0.49) ALDH1A1PPARGPPARDPPARAKDM4E
SCHEMBL2483134 0.85 ALDH1A1 (0.49) ALDH1A1PPARGPPARDPPARAHTT
SCHEMBL8481621 0.84 ALDH1A1 (0.71) ALDH1A1PPARGPPARDPPARAHTT
SCHEMBL30644304 0.82 ALDH1A1 (0.69) ALDH1A1PPARGPPARDPPARAHTT
SCHEMBL557409 0.82 ALDH1A1 (0.69) ALDH1A1PPARGPPARDPPARAHTT
SCHEMBL1812946 0.82 KDM1A (0.45) ALDH1A1PPARGPPARDPPARAHTT
SCHEMBL7666743 0.81 HTT (0.55) ALDH1A1HTTKDM4EMITFLMNA
SCHEMBL3343652 0.81 ALDH1A1 (0.67) ALDH1A1PPARGPPARDPPARAHTT
SCHEMBL28743518 0.81 ALDH1A1 (0.45) ALDH1A1PPARGPPARDPPARAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150349-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2024-05-09 US disclosed
EP-3681885-B1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-02-28 EP disclosed
EP-3681885-B1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-02-28 EP disclosed
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors FORMA THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors FORMA THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors FORMA THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
CN-116589454-A Aromatic heterocyclic compound, preparation method and medical application thereof 中国医药研究开发中心有限公司 2023-08-15 CN disclosed
CN-116478134-A SSRI/5-HT 1A Double-target antidepressant formylpiperidine compound and preparation method and application thereof 上海医药工业研究院有限公司 2023-07-25 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20220169647-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. 2022-06-02 US disclosed
WO-2012040641-A2 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2012-03-29 WO disclosed
EP-2346332-A1 PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES Medivation Technologies, Inc. (US) 2011-07-27 EP disclosed
WO-2011051275-A1 LITHIUM SULFUR BATTERY SOLVAY FLUOR GMBH (DE) 2011-05-05 WO disclosed
WO-2010051501-A1 PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES MEDIVATION TECHNOLOGIES, INC. (US) 2010-05-06 WO disclosed
EP-2114867-A1 AMINOAMIDES AS OREXIN ANTAGONISTS F. Hoffmann-Roche AG (CH) 2009-11-11 EP disclosed
WO-2008107335-A1 AMINOAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-09-12 WO disclosed
EP-1919875-A2 PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS Astex Therapeutics Limited (GB) 2008-05-14 EP disclosed
WO-2006136829-A2 PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2006-12-28 WO disclosed
EP-1324993-A2 SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2003-07-09 EP disclosed
WO-2001079187-A2 SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES CYTOVIA, INC. (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150349-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS EP300, CREBBP, BRD3 ALDH1A1 3405/4885PPARG 1116/4885PPARD 1730/4885
US-20220169647-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS EP300, CREBBP, BRD3 ALDH1A1 3405/4885PPARG 1116/4885PPARD 1730/4885
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors EP300, CREBBP, BRD3 ALDH1A1 3405/4885PPARG 1116/4885PPARD 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.